This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), AbCellera Biologics (ABCL) and PACS Group Inc (PACS)

Tipranks - Tipranks - Wed May 13, 8:28AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phreesia (PHR), AbCellera Biologics (ABCL) and PACS Group Inc (PACS).

Claim 55% Off TipRanks

Phreesia (PHR)

Truist Financial analyst Jailendra Singh maintained a Hold rating on Phreesia today. The company’s shares closed last Monday at $9.57.

According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of -12.4% and a 35.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

Phreesia has an analyst consensus of Moderate Buy, with a price target consensus of $15.43, representing a 52.8% upside. In a report issued on April 28, TipRanks – xAI also reiterated a Hold rating on the stock with a $10.00 price target.

See the top stocks recommended by analysts >>

AbCellera Biologics (ABCL)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbCellera Biologics today. The company’s shares closed last Monday at $5.25.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 18.8% and a 58.1% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Madrigal Pharmaceuticals, and Protagonist Therapeutics. ;'>

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $8.75, which is a 59.7% upside from current levels. In a report issued on May 5, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $7.00 price target.

PACS Group Inc (PACS)

In a report released today, David S Macdonald from Truist Financial maintained a Buy rating on PACS Group Inc. The company’s shares closed last Monday at $31.90.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 10.0% and a 57.8% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for PACS Group Inc with a $45.50 average price target, which is a 35.7% upside from current levels. In a report issued on April 28, TipRanks – Google also reiterated a Buy rating on the stock with a $39.00 price target.

Read More on PHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).